These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort. Waters MJ; Limaye V Clin Rheumatol; 2018 Feb; 37(2):543-547. PubMed ID: 28905130 [TBL] [Abstract][Full Text] [Related]
14. Anti-HMGCR autoantibodies in self-limiting statin-induced myopathy. Keating P; Young J; George P; Florkowski C; Spellerberg M; Kennedy N Int J Rheum Dis; 2017 Dec; 20(12):2179-2181. PubMed ID: 28185416 [No Abstract] [Full Text] [Related]
15. Immune-mediated necrotizing myopathy due to statins exposure. Villa L; Lerario A; Calloni S; Peverelli L; Matinato C; DE Liso F; Ceriotti F; Tironi R; Sciacco M; Moggio M; Triulzi F; Cinnante C Acta Myol; 2018 Dec; 37(4):257-262. PubMed ID: 30944904 [TBL] [Abstract][Full Text] [Related]
16. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Werner JL; Christopher-Stine L; Ghazarian SR; Pak KS; Kus JE; Daya NR; Lloyd TE; Mammen AL Arthritis Rheum; 2012 Dec; 64(12):4087-93. PubMed ID: 22933019 [TBL] [Abstract][Full Text] [Related]
18. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins. Lahaye C; Beaufrére AM; Boyer O; Drouot L; Soubrier M; Tournadre A Joint Bone Spine; 2014 Jan; 81(1):79-82. PubMed ID: 23953224 [TBL] [Abstract][Full Text] [Related]